Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B.

Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, Chen CY, Hsieh TY, Lin HC, Chuang WL; Taiwan NA-Registry Group.

J Gastroenterol Hepatol. 2014 Jan;29(1):185-92. doi: 10.1111/jgh.12416.

PMID:
24354995
2.

[Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].

Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.

Mikrobiyol Bul. 2009 Jul;43(3):425-32. Turkish.

PMID:
19795617
3.

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.

Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y.

Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472. Epub 2013 Mar 1.

4.

Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.

Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH, Hu TH.

J Gastroenterol Hepatol. 2014 Mar;29(3):568-75.

PMID:
24716215
5.

Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.

Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bömmel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group.

Hepatology. 2011 Aug;54(2):443-51. doi: 10.1002/hep.24406. Erratum in: Hepatology. 2011 Dec;54(6):2280.

PMID:
21563196
6.

[A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].

Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, Hou JL.

Zhonghua Nei Ke Za Zhi. 2006 Nov;45(11):891-5. Chinese.

PMID:
17313873
7.

Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.

Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y.

Clin Exp Med. 2012 Sep;12(3):159-64. doi: 10.1007/s10238-011-0160-7. Epub 2011 Oct 15.

PMID:
22002708
8.

Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine.

Kamezaki H, Kanda T, Arai M, Wu S, Nakamoto S, Chiba T, Maruyama H, Fujiwara K, Kanai F, Imazeki F, Nomura F, Yokosuka O.

Int J Med Sci. 2013;10(5):567-74. doi: 10.7150/ijms.5795. Epub 2013 Mar 15.

9.

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.

Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F.

Eur J Gastroenterol Hepatol. 2014 Feb;26(2):146-54. doi: 10.1097/MEG.0b013e328365c3e5.

PMID:
24025974
10.
11.

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.

Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group.

J Hepatol. 2010 Apr;52(4):493-500. doi: 10.1016/j.jhep.2010.01.012. Epub 2010 Feb 4.

PMID:
20185191
12.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
13.

[Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].

Ji FZ, Wang L, Yang BH, Zhao JJ, Liu F, Xue Y, Li T.

Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):280-4. doi: 10.3760/cma.j.issn.1007-3418.2012.04.011. Chinese.

PMID:
22964149
14.

Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B.

Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S.

Dig Dis Sci. 2012 May;57(5):1358-65. doi: 10.1007/s10620-011-1988-0. Epub 2011 Dec 2.

PMID:
22134785
15.

Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.

Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.

J Gastroenterol Hepatol. 2008 Sep;23(9):1320-6. doi: 10.1111/j.1440-1746.2008.05455.x. Epub 2008 Jun 28.

PMID:
18554238
16.

A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.

Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH.

J Antimicrob Chemother. 2012 Mar;67(3):696-9. doi: 10.1093/jac/dkr495. Epub 2011 Dec 15.

17.

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.

Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.

J Hepatol. 2010 Sep;53(3):449-54. doi: 10.1016/j.jhep.2010.03.020. Epub 2010 May 25.

PMID:
20646776
18.

Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.

Singal AK, Fontana RJ.

Aliment Pharmacol Ther. 2012 Mar;35(6):674-89. doi: 10.1111/j.1365-2036.2011.04990.x. Epub 2012 Jan 19.

19.

Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.

Lim YS, Lee TH, Heo NY, Shim JH, Lee HC, Suh DJ.

Antivir Ther. 2012;17(1):53-60. doi: 10.3851/IMP1914.

PMID:
22267469
20.

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.

Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O.

Scand J Gastroenterol. 2011 Sep;46(9):1111-7. doi: 10.3109/00365521.2011.584898. Epub 2011 May 30.

PMID:
21623676
Items per page

Supplemental Content

Write to the Help Desk